RT Journal Article
SR Electronic
T1 Metronidazole in the treatment of non-specific vaginitis (NSV).
JF The British Journal of Venereal Diseases
JO Br J Vener Dis
FD BMJ Publishing Group Ltd
SP 171
OP 174
DO 10.1136/sti.60.3.171
VO 60
IS 3
A1 Jerve, F
A1 Berdal, T B
A1 Bohman, P
A1 Smith, C C
A1 Evjen, O K
A1 Gjønnaess, H
A1 Gaasemyr, M
A1 Hausken, L
A1 Hesla, K
A1 Hoftvedt, E
YR 1984
UL http://sti.bmj.com/content/60/3/171.abstract
AB In a large multicentre study of 429 patients with the usual signs and symptoms of non-specific vaginitis (NSV), we studied the effect of different doses of metronidazole. The patients were divided into five treatment groups as follows: group A was given 400 mg metronidazole three times daily for seven days, group B 2000 mg as a single dose, group C 2000 mg on days 1 and 2, group D 2000 mg on days 1 and 3, and group E was given 1200 mg metronidazole once daily for five days. At follow up examination four weeks from the start of treatment, patients in groups D and E showed the best clinical results with cure rates of 94.0% and 93.6% respectively. In addition the rate of reisolation of Gardnerella vaginalis was lowest in group D. We therefore recommend metronidazole 2000 mg on days 1 and 3 as routine treatment for non-specific or vaginitis associated with gardnerella.